1例中西药联合治疗2型糖尿病患者痛风发作期的药学监护

doi:10.19803/j.1672-8629.20230759

中国药物警戒 ›› 2024, Vol. 21 ›› Issue (4): 451-453.
DOI: 10.19803/j.1672-8629.20230759

1例中西药联合治疗2型糖尿病患者痛风发作期的药学监护

陈丽叶¹, 朱丽^2,*, 贡磊磊³

¹昆山市中医医院药学部,江苏昆山 215300;
²中国中医科学院广安门医院药学部北京 100053;
³首都医科大学附属北京妇产医院药学部,北京 100026

收稿日期:2023-12-05 出版日期:2024-04-15 发布日期:2024-04-18
通讯作者: ^*朱丽,女,硕士,主管药师,临床药学。E-mail：zhuli881104@163.com
作者简介:陈丽叶,女,硕士,主管中药师,临床中药学。
基金资助:
国家自然科学基金资助项目（82204698）; 中国中医科学院广安门医院科研结余经费项目（2023085）

Pharmaceutical care of a patient with type 2 diabetes mellitus treated with a combination of traditional Chinese and Western medicine during acute exacerbation of gout

CHEN Liye¹, ZHU Li^2,*, GONG Leilei³

¹Department of Pharmacy, Kunshan Hospital of Traditional Chinese Medicine, Kunshan Jiangsu 215300, China;
²Department of Pharmacy, Guang'anmen Hospital of China Academy of Chinese Medical Sciences, Beijing 100053, China;
³Department of Pharmacy, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing 100026, China

Received:2023-12-05 Online:2024-04-15 Published:2024-04-18

摘要/Abstract

摘要： 目的探讨临床药师在1例2型糖尿病患者痛风急性发作期治疗过程中的作用。方法临床药师参与2型糖尿病患者痛风急性发作期的药物治疗,分析患者血糖控制不佳的药物原因,筛选降糖药物对血尿酸的影响,建议选用钠-葡萄糖共转运蛋白2抑制剂（SGLT-2i）,同时优化降糖、痛风治疗的中西药方案。结果患者肿痛症状明显缓解,血糖平稳下降。结论临床药师通过参与1例2型糖尿病患者痛风急性发作期的药学监护,协助医师优化治疗方案,对患者进行个体化用药,在临床治疗过程中发挥了积极作用。

关键词: 2型糖尿病, 痛风, 急性发作, 中西药联合, 降糖, 高尿酸血症, 高脂血症, 血糖, 血尿酸

Abstract: Objective To explore the role of clinical pharmacists in the treatment of a patient with type 2 diabetes mellitus in the acute exacerbation stage of gout. Methods Clinical pharmacists participated in the treatment of a patient with type 2 diabetes mellitus in the stage of acute exacerbation, analyzed the drug-related causes of poor blood glucose control, studied the effect of hypoglycemic drugs on blood uric acid, recommended switch to SGLT-2i and optimized the Chinese and Western medicine regimens for hypoglycemic and gout treatment. Results The symptoms of swelling and pain were significantly alleviated, and the blood glucose decreased steadily. Conclusion Clinical pharmacists can play an active role in clinical treatment by participating in the pharmaceutical care of patients with type 2 diabetes mellitus during acute exacerbation of gout, assisting physicians in optimizing treatment plans, and providing individualized medication to patients.

Key words: diabetes mellitus type 2, gout, acute exacerbation, combination of traditional Chinese and Western medicine, reduction of blood glucose, hyperuricemia, hyperlipidemia, blood glucose, blood uric acid

中图分类号:

R919.693

陈丽叶, 朱丽, 贡磊磊. 1例中西药联合治疗2型糖尿病患者痛风发作期的药学监护[J]. 中国药物警戒, 2024, 21(4): 451-453.

CHEN Liye, ZHU Li, GONG Leilei. Pharmaceutical care of a patient with type 2 diabetes mellitus treated with a combination of traditional Chinese and Western medicine during acute exacerbation of gout[J]. Chinese Journal of Pharmacovigilance, 2024, 21(4): 451-453.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://www.zgywjj.com/CN/10.19803/j.1672-8629.20230759

https://www.zgywjj.com/CN/Y2024/V21/I4/451

参考文献

[1] XU WY, CUI XL.Literature analysis of 45 cases of drug-induced hyperuricemia[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2020, 17(9): 574-577.
[2] QASEEM A, MCLEAN RM, STARKEY M, et al.Diagnosis of acute gout: a clinical practice guideline from the American College of Physicians[J]. Ann Intern Med, 2017, 166(1): 52-57.
[3] TOYOKI D, SHIBATA S, KURIBAYASHI-OKUMA E, et al.Insulin stimulates uric acid reabsorption via regulating urate transporter 1 and ATP-binding cassette subfamily G member 2[J]. Am J Physiol Renal Physiol, 2017, 313(3): F826-F834.
[4] XU D, ZHU XX, ZOU HJ, et al.Recommendations for the diagnosis and treatment of gout in China[J]. Chin J Intern Med(中华内科杂志), 2023, 62(9): 1068-1074.
[5] Rheumatology Committee of Chinese Association of Integrative Medicine. Guidelines for the diagnosis and treatment of gout and hyperuricemia with integrated traditional Chinese and Western medicine[J]. Journal of Traditional Chinese Medicine(中医杂志), 2023, 64(1): 98-106.
[6] LI SD, XIE F, LIU YL, et al.Network meta-analysis of oral Chinese patent medicine in treatment of gouty[J]. Chinese Traditional and Herbal Drugs(中草药), 2021, 52(13): 3980-3993.
[7] Chinese Diabetes Society.Guideline for the prevention and treatment of type 2 diabetes mellitus in China (2020 edition)[J].Chinese Journal of Diabetes(中华糖尿病杂志), 2021, 13(4): 315-409.
[8] MCCORMICK N, O'CONNOR MJ, YOKOSE C, et al. Assessing the causal relationships between insulin resistance and hyperuricemia and gout using bidirectional mendelian randomization[J]. Arthritis Rheumatol, 2021, 73(11): 2096-2104.
[9] Chinese Society of Diabetes. Expert consensus on the clinical application of hypoglycemic drugs in Chinese adult patients with type 2 diabetes mellitus complicated with heart and kidney diseases[J]. Chinese Journal of Diabetes(中华糖尿病杂志), 2020, 12(6): 369-381.
[10] LA GROTTA R, DE CANDIA P, OLIVIERI F, et al.Anti-inflammatory effect of SGLT-2 inhibitors via uric acid and insulin[J]. Cell Mol Life Sci, 2022, 79(5): 273-286.
[11] DAVYDCHIK E, SNEZHITSKIY V, MARTINKEVICH O.Effect of hypoglycemic drugs on uric acid levels[J]. Recipe, 2022, 25(4): 516-520.
[12] XIANG YF, SUN H, CHEN Y, et al.Medication safety and combined medication in patients with type 2 diabetes mellitus[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2022, 19(3): 313-316.
[13] BENDOTTI G, MONTEFUSCO L, PASTORE I, et al.The anti-inflammatory and immunological properties of SGLT-2 inhibitors[J]. Endocrinol Invest, 2023, 46(12): 2445-2452.
[14] SUN SF, PANG WL, XIE XC, et al.Clinical observation of the addition and subtraction of Lingming Simiao decoction in the treatment of type 2 diabetes mellitus with acute attack of gout[J]. Chinese Journal of Traditional Chinese Medicine(中华中医药学刊), 2023, 41(12): 231-234.
[15] MENG Q, MENG W, BIAN H, et al.Total glucosides of paeony protects THP-1 macrophages against monosodium urate-induced inflammation via MALAT1/miR-876-5p/NLRP3 signaling cascade in gouty arthritis[J]. Biomedicine & Pharmacotherapy, 2021, 138: 111413.
[16] HUO GL.Clinical study of the treatment of gouty arthritis in the acute phase (damp heat betting type) with heat clearing and dampness removal formula[D]. Changchun: Changchun University of Traditional Chinese Medicine(长春中医药大学), 2022.
[17] WANG H, GU CJ, TONG XL.Mulberry leaves, mulberry branches, and mulberry white bark experience in the treatment of diabetes - Tong Xiaolin's three flavors and small recipes[J]. Jilin Traditional Chinese Medicine(吉林中医药), 2019, 39(11): 1463-1465.
[18] CHEN L, BAI Y, CHEN X, et al.Study on the lipid-lowering effect of honey mulberry white bark in vivo[J]. World Science and Technology-Modernization of Traditional Chinese Medicine(世界科学技术-中医药现代化), 2021, 23(9): 3337-3343.
[19] YAO L, JIAO XQ, WANG PF.Experience of authoritative experts in the treatment of constipation by traditional Chinese medicine form 1979 to 2021[J]. Guangming Journal of Traditional Medicine(光明中医), 2023, 38(24): 474-4744.
[20] Ventilation Professional Committee of Rheumatology and Immunology Branch of Chinese Medical Doctor Association. Gout diagnosis and treatment standards[J]. Chinese Journal of Internal Medicine(中华内科杂志), 2020, 59(6): 421-426.

1例中西药联合治疗2型糖尿病患者痛风发作期的药学监护

Pharmaceutical care of a patient with type 2 diabetes mellitus treated with a combination of traditional Chinese and Western medicine during acute exacerbation of gout

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	黄曙光, 张学农. 多肽BR0336在小鼠2型糖尿病合并非酒精性脂肪性肝炎模型上的初步药效学研究[J]. 中国药物警戒, 2024, 21(4): 415-421.
[2]	姚荣妹, 毛鑫, 徐英莉, 张之斌, 高英杰, 包蕾, 鲍岩岩, 孟凤仙, 崔晓兰. 土藤草颗粒对微晶型尿酸钠致家兔急性痛风性关节炎的药效学研究[J]. 中国药物警戒, 2024, 21(3): 263-268.
[3]	靳生菊, 周苗, 张佳宁, 葛宫慧, 张廷剑, 孟繁浩. 新型黄嘌呤氧化酶抑制剂对痛风治疗的研究进展[J]. 中国药物警戒, 2024, 21(2): 223-228.
[4]	宋东宁, 刘静, 张才煜, 刘阳, 何兰, 张庆生. 纸喷雾离子化质谱快速筛查复杂基质中的西格列汀[J]. 中国药物警戒, 2023, 20(4): 388-391.
[5]	王姗, 黄举凯, 吴宏辉, 温雅璐, 张力, 王建华, 杨晓晖. 2型糖尿病合并非酒精性脂肪性肝病KKAy动物模型的探索与评价[J]. 中国药物警戒, 2023, 20(3): 273-276.
[6]	魏安华, 漆建军, 王璐, 曾露, 贡雪芃, 江莹. 953例口服降糖药不良反应/事件报告分析[J]. 中国药物警戒, 2023, 20(12): 1415-1420.
[7]	穆思聪, 王卓, 卢俊阳, 纪立伟, 柳鑫. 吡格列酮对2型糖尿病患者血浆脂联素影响的Meta分析[J]. 中国药物警戒, 2022, 19(9): 1015-1018.
[8]	杨柳, 石凤华, 马丽娟. 基于Logistic回归分析格列美脲不良反应影响因素及其对治疗2型糖尿病有效性的影响[J]. 中国药物警戒, 2022, 19(9): 1030-1034.
[9]	孟康康, 王春婷, 熊玮仪. 普萘洛尔片剂治疗婴幼儿血管瘤的安全性分析[J]. 中国药物警戒, 2022, 19(7): 749-751.
[10]	向玉芳, 孙辉, 陈月, 王宁生, 罗世书, 张智, 冯变玲. 2型糖尿病降糖药不良反应及联合用药情况分析[J]. 中国药物警戒, 2022, 19(3): 313-316.
[11]	蔡俊, 卫菁, 纪立伟. 达格列净片致正常血糖酮症2例分析[J]. 中国药物警戒, 2021, 18(3): 271-273.
[12]	陈琪莹, 黄丹丹, 陈添玉. 高剂量卡格列净对2型糖尿病安全性的Meta分析[J]. 中国药物警戒, 2021, 18(2): 150-154.
[13]	陈捷, 吴磊, 吴杨霞, 潘敉, 段自皞, 朱枝祥. 高脂血症患者他汀类用药依从性影响因素探讨及风险预测[J]. 中国药物警戒, 2021, 18(11): 1070-1074.
[14]	蓝晓红, 周永刚, 臧菊香, 吴冬妮, 李祥, 许锐, 陈曙东, 于浩, 张烨. 临床药师主导的社区药学服务对老年患者他汀类药物治疗服务系统构建与评价的影响[J]. 中国药物警戒, 2020, 17(9): 594-599.
[15]	徐菀佚, 崔向丽. 45例药源性高尿酸血症文献分析[J]. 中国药物警戒, 2020, 17(9): 574-577.